Global biopharmaceutical company AstraZeneca has formed a partnership with the National Comprehensive Cancer Network® Oncology Research Program seeking proposals for improving care processes for patients with unresectable stage III and stage IV non-small cell lung cancer (NSCLC). The collaborative partnership is inviting researchers from NCCN’s 28 member institutions to submit a letter of intent by July 9 2019. The team notes all funded programs must:
Promote evidence-based care
Be sustainable after the award funding is complete
Collect data and report outcomes
Aim to enhance clinical outcomes, patient satisfaction, or provider satisfaction
Address patient variability
Promote administrative and system efficiency
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).